Author

Scott A. Ely

Memorial Sloan Kettering Cancer CenterORCID 0000-0001-6382-6772Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Assay:proteomics· 1

Frequent Co-Authors

David S. JayabalaniD· 1 shared Gang LiniD· 1 shared Maurizio Di Liberto· 1 shared Rubén Niesvizky· 1 shared Selina Chen‐KiangiD· 1 shared Tomer Martin MarkiD· 1 shared Xiangao HuangiD· 1 shared Zhengming CheniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

David S. JayabalanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintOct 14, 2025

CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma

Xiangao Huang, David S. Jayabalan, Maurizio Di Liberto…·Selina Chen‐Kiang

This paper shows CDK4/6 inhibition enhances immunomodulatory drug therapy in multiple myeloma by reversing MEIS2 suppression of CRL4CRBN and reducing BCMA signaling.

DOI 10.1101/2025.10.14.681840

humanproteomics

𝕏 PostBluesky